Parthasaradhi Tanguturi

For over two decades, Parthasaradhireddy Tanguturi has been engaged in drug discovery and research- preclinical biology efforts towards developing new drugs in the area of pain and addiction, Central Nervous System disorders, Metabolic disorders, anti-cancer, anti-inflammatory, anti-infectives. The targets of these NIH and Industrial-based projects include GPCRs (serotonin, Opioid, Dopamine), Nuclear hormone receptors, inhibitors of protein-protein interactions, Peptides, and Kinases. As a lead biologist in these projects, he is instrumental in identification of lead molecules with great binding affinity, functional potency, selectivity profile with acceptable PK/PD ratio and In vivo efficacy. He has also been involved in target identification and validation for new drug targets, assay development, Identification of hit molecules from high throughput screening, reviewing and interpreting data obtained from various supporting functions, such as DMPK, toxicology, molecular biology.

Areas of Research: 

G-protein coupled receptors (GPCRs)
Drug discovery
Alzheimer’s
Central nervous system (CNS)
Oncology
Pain therapeutics

Awards:

• Outstanding Achiever Award for exceptional performance and Value Star Award for exhibiting customer focus at Aurigene Discovery Technologies (2014-2015).
• International Nacrotics Research Conference (INRC) travel award, Michigan,2024
• Certified Radiation Safety Officer – Awarded by Baba Atomic Research Center (BARC), India (2005).
• Training at Montreal (Canada) for receptor binding studies on GPCR using Top-count NXT scintillation Counter, sponsored by Perkin-Elmer Life Sciences, Canada (2006).
• Attend workshop on liquid handling system for HTS studies, sponsored by Beckmann Coulter, London, UK (2006).

Professional Organizations:

Member: Society for Neuroscience
Editorial board for Biochemical Genetics

Publications:

1. Tanguturi P, Mitchell S, Moukha-Chafiq O, Zhang S, Tillotson J, Ananthan S, Augelli-Szafran CE, Streicher JM. Development of Delta Opioid Receptor Antagonists Which Prevent Alzheimer's Disease-Like Pathology in the 5X-Familial Alzheimer's Disease [5XFAD] Mouse Model. ACS Pharmacol Transl Sci. 2025 Aug 5;8(9):3346-3370. doi: 10.1021/acsptsci.5c00509. PMID: 40969869; PMCID: PMC12441865.
2. Chimeric Hsp90β-selective Inhibitors Confer Enhanced Affinity, Se-lectivity, and Drug-like Properties
   Michael A. Serwetnyka,‡, Parthasaradhireddy Tanguturib,‡, Terin D’Amicoa, Yoshihiro Morishimac, Mi-randa Lauc, Ian Mersicha,d, Deborah Barlowe, Karen L. Houseknechte, Yoichi Osawac, John M. Strei-cherb, Aktar Alid, and Brian S. J. Blagga,*Accepted-Journal of Medicinal Chemistry
3. O'Brien ES, Wang J, Tanguturi P, Li M, White E, Shiimura Y, Paul B, Appourchaux K, Kumar KK, Huang W, Majumdar S, Traynor JR, Streicher JM, Chen C, Kobilka BK.
   Discovery and dynamic pharmacology of μ-opioid receptor positive allosteric modulators. bioRxiv [Preprint]. 2026 Feb 21:2026.02.20.707058. doi: 10.64898/2026.02.20.707058. PMID: 41757031; PMCID: PMC12934670.
4.  Palomino, S.M.; Levine, A.A.; Liktor-Busa, E.; Tanguturi, P.; Streicher, J.M.; Largent-Milnes,
   T.M. Brain Hsp90 Inhibition Mitigates Facial Allodynia in a Rat Model of CSD Headache and Upregulates Endocannabinoid Signaling in the PAG. Pharmaceuticals 2025, 18, 1430. https://doi.org/10.3390/ph18101430.
5. Duron DI, Tanguturi P (Co-First Author), Campbell CS, Chou K, Bejarano P, Gabriel KA, Bowden JL, Mishra S, Brackett C, Barlow D, Houseknecht KL, Blagg BSJ, and Streicher JM. 2024. Inhibiting Spinal Cord- Specific Hsp90 Isoforms Reveals a Novel Strategy to Improve the Therapeutic Index of Opioid Treatment. Scientific Reports. 14:14715. PMID 38926482.